ARWR - ARROWHEAD PHARMACEUTICALS, INC.

QQQ $ 468.28 $ 9.96 (2.17 %)

DIA $ 409.73 $ 1.01 (0.25 %)

SPY $ 554.79 $ 5.63 (1.03 %)

TLT $ 100.61 $ -0.08 (-0.08 %)

GLD $ 232.25 $ -0.37 (-0.16 %)

Previous Close

$ 20.94

Open

Bid

$ 20.93 x 100

Ask

-- x --

Day's Range

-- - --

52 Week Range

$ 20.63 - $ 39.83

Volume

1,422,348

Average Volume

Market Cap

2.6B

Beta (5Y Monthly)

$ 1.10

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-08-2024	06-30-2024	10-Q
2	05-09-2024	03-31-2024	10-Q
3	02-06-2024	12-31-2023	10-Q
4	11-29-2023	09-30-2023	10-K
5	08-07-2023	06-30-2023	10-Q
6	05-02-2023	03-31-2023	10-Q
7	02-06-2023	12-31-2022	10-Q
8	11-28-2022	09-30-2022	10-K
9	08-04-2022	06-30-2022	10-Q
10	05-10-2022	03-31-2022	10-Q
11	02-02-2022	12-31-2021	10-Q
12	11-22-2021	09-30-2021	10-K
13	08-05-2021	06-30-2021	10-Q
14	05-04-2021	03-31-2021	10-Q
15	02-04-2021	12-31-2020	10-Q
16	11-23-2020	09-30-2020	10-K
17	08-05-2020	06-30-2020	10-Q
18	05-07-2020	03-31-2020	10-Q
19	02-05-2020	12-31-2019	10-Q
20	11-25-2019	09-30-2019	10-K
21	08-05-2019	06-30-2019	10-Q
22	05-08-2019	03-31-2019	10-Q
23	02-07-2019	12-31-2018	10-Q
24	12-11-2018	09-30-2018	10-K
25	08-07-2018	06-30-2018	10-Q
26	05-08-2018	03-31-2018	10-Q
27	02-09-2018	12-31-2017	10-Q
28	12-12-2017	09-30-2017	10-K
29	08-03-2017	06-30-2017	10-Q
30	05-03-2017	03-31-2017	10-Q
31	02-06-2017	12-31-2016	10-Q
32	12-14-2016	09-30-2016	10-K
33	08-09-2016	06-30-2016	10-Q
34	05-10-2016	03-31-2016	10-Q
35	02-09-2016	12-31-2015	10-Q
36	12-14-2015	09-30-2015	10-K
37	08-04-2015	06-30-2015	10-Q
38	05-11-2015	03-31-2015	10-Q
39	02-09-2015	12-31-2014	10-Q
40	11-25-2014	09-30-2014	10-K

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

The FDA Granted Breakthrough Therapy Desig...
09/10/2024 11:31:40

Cantor Fitzgerald Reiterates Overweight on...
09/09/2024 16:56:42

Cantor Fitzgerald analyst Josh Schimmer reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Overweight.

HC Wainwright & Co. Reiterates Buy on Arro...
09/05/2024 11:04:21

HC Wainwright & Co. analyst Patrick Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $60 pric...

HC Wainwright & Co. Reiterates Buy on Arro...
09/03/2024 17:30:28

HC Wainwright & Co. analyst Patrick Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $60 pric...

Arrowhead Pharmaceuticals shares are tradi...
09/03/2024 11:56:32

Arrowhead's Plozasiran Meets All Primary a...
09/03/2024 07:09:14

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced results from the Phase 3 PALISADE study of investigational plozas...

Arrowhead Pharmaceuticals Announced That I...
08/21/2024 11:41:25

Arrowhead Pharmaceuticals To Advance Two N...
08/14/2024 17:31:49

- Company hosting an obesity/metabolic R&D webinar today, August 14, 2024, at 2:00 pm ET as Part IV of the 2024 Summer Seri...

B. Riley Securities Reiterates Buy on Arro...
08/12/2024 16:04:42

B. Riley Securities analyst Mayank Mamtani reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $55 price target.

Arrowhead Pharmaceuticals Announces $500M ...
08/08/2024 21:03:21

- Balance sheet strengthened with long-term, non-dilutive capital- $400 million funded at close with the potential to draw an a...

Arrowhead Pharma Q3 2024 Revenue $0 Down F...
08/08/2024 20:09:28

Arrowhead Pharma Q3 2024 GAAP EPS $(1.38) ...
08/08/2024 20:08:36

Arrowhead Pharma (NASDAQ:ARWR) reported quarterly losses of $(1.38) per share which missed the analyst consensus estimate of $(...

HC Wainwright & Co. Reiterates Buy on Arro...
07/23/2024 17:18:47

HC Wainwright & Co. analyst Patrick Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $60 pric...

Chardan Capital Maintains Buy on Arrowhead...
07/17/2024 18:35:02

Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $60 price target.

sp-global-to-rally-more-than-13-here-are-10-top-analyst-forecasts-for-friday

S&P Global To Rally More Than 13%? Here Ar...
07/05/2024 13:34:49

HC Wainwright & Co. Maintains Buy on Arrow...
07/05/2024 10:09:29

HC Wainwright & Co. analyst Patrick Trucchio maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and lowers the price ta...

Chardan Capital Maintains Buy on Arrowhead...
06/26/2024 12:07:01

Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $60 price target.

Arrowhead Pharmaceuticals To Advance Inves...
06/25/2024 17:58:38

– Based on results in the Phase 2 MUIR clinical study, the Phase 3 CAPITAN trial is designed to enroll patients with mixed hype...

why-arrowhead-pharmaceuticals-arwr-stock-is-seeing-blue-skies

Why Arrowhead Pharmaceuticals (ARWR) Stock...
06/24/2024 20:24:30

Arrowhead Pharmaceuticals shares are trading higher by more than 6% during Monday's session. The company announced that it ...

Arrowhead Pharmaceuticals Unveils Obesity ...
06/24/2024 11:45:22

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) today announced that preclinical data on ARO-INHBE, an investigational RNAi-based...